ReviewInternational journal of hematology2016
Ruxolitinib dose management as a key to long-term treatment success.
Review in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review.Clinical pharmacokinetics · 2023Pooled it
- Development and validation of an LC-MS/MS method for ruxolitinib quantification: advancing personalized therapy in hematologic malignancies.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Article
- JAK Inhibitors in Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024Review
- Article
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.Oncotarget · 2017Article
- Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.Internal medicine (Tokyo, Japan) · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The Janus kinase 1 (JAK1) and JAK2 inhibitor ruxolitinib is currently the only therapy indicated for intermediate- or high-risk myelofibrosis. Results from clinical trials and experience in clinical practice have shown that ruxolitinib reduces myelofibrosis-related splenomegaly and symptom burden, and improves quality-of-life measures. In addition, ruxolitinib was associated with a survival advantage compared with placebo or conventional therapy in controlled trials. However, owing to the myelosuppressive effects of JAK2 inhibition, ruxolitinib is associated with decreases in hemoglobin and platelet counts, particularly during the first 8-12 weeks of therapy. Close monitoring of blood counts and careful dose management, particularly early in the course of therapy, are essential to avoid unnecessary cytopenias that may prompt premature treatment discontinuation by patients who otherwise would benefit from continued therapy. In general, starting doses and dose reductions should be used as recommended by the prescribing information based on platelet counts. A dose-escalation approach at the start of therapy is only recommended for patients with platelet counts of 50-100 × 10(9)/L. If possible, maximum tolerated doses should be maintained and extended treatment interruptions should be avoided to prevent lack or loss of treatment responses. An individualized dosing approach is key to long-term treatment success.
Indexed as
Identifiers
27567907What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.